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Abstract: Cardiovascular effects of opioid withdrawal have long been studied. It was reported that patients with underly-
ing ischemic heart disease and atherosclerotic vessels may be complicated by a sudden physical and emotional
stress due to withdrawal syndrome. But some other believes sudden increase in catecholamine level as a sym-
pathetic overflow might effect on heart with and without underlying ischemia. In the current study, a patient on
methadone maintenance therapy (MMT) who experienced myocardial infarction (MI) after taking naltrexone
was described.
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1. Introduction
Cardiovascular effects of opioid withdrawal have long been
studied. Opioid withdrawal induces agitation, muscular
pain, vomiting, diaphoresis, rhinorrhea, mydriasis as well as
tachycardia and hypertension, which could be related to a
transient increase in catecholamines. Older patients with un-
derlying cardiac ischemia could be at greater risk for cardiac
events following abrupt withdrawal (1, 2); although this is-
sue has been challenged (3). It was reported that patients
with underlying ischemic heart disease and atherosclerotic
vessels may be complicated by a sudden physical and emo-
tional stress due to withdrawal syndrome. But some other
believes sudden increase in catecholamine level as a sympa-
thetic overflow might effect on heart with and without under-
lying ischemia. In the current study, a patient on Methadone
Maintenance Therapy (MMT) who experienced myocardial
infarction (MI) after taking naltrexone was described.
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2. Case presentation:
A 64-year-old man was admitted in emergency toxicology
ward with altered mental status and agitation. His symptoms
were started abruptly following consumption of naltrexone
and were progressed to respiratory distress and tachypnea.
On medical history, he was diabetic and hypertensive. He
was also on regular consumption of methadone (40 mil-
ligram daily) for recent 4 years following 20 years opium ad-
diction. He had blood pressure 170/110 mmHg, heart rate:
90/minute, respiratory rate 24/minute, tympanic tempera-
ture 36.8◦C, and serum blood sugar 504 mg/dL on arrival.
Due to decreased level of consciousness and to maintain the
airway, he was intubated and underwent mechanical venti-
lation. Electrocardiography (ECG) on admission revealed old
silent inferolateral myocardial infarction (MI) that showed
in figure 1. Intravenous nitroglycerin and regular insulin
were administered for controlling high blood pressure and
hyperglycemia and he was admitted in intensive care unit
(ICU). After a while, his blood pressure reached to 200/150
mmHg and dynamic changes were occurred on the ECG
as revealed in figure 2, that illustrate an acute inferior my-
ocardial infarction associated with positive troponin-I level.
Bedside echocardiography revealed global hypokinesis along
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Figure 1: Brain magnetic resonance imaging (MRI) and cerebral
resonance angiography.
Figure 2: Axial and coronal section cut of chest angiogram.
with akinesis in apex and inferior wall and severe hypokine-
sis in inferior septal and anteroseptal wall. Left ventricular
ejection fraction reported as 30-35%. Systolic pulmonary ar-
terial pressure reported 30 mmHg and no pericardial effusion
was detected. Unfortunately, percutaneous coronary inter-
vention was not accessible, so medical treatment for acute
coronary syndrome was started based on recommendations
of cardiologist consult. He was referred to cardiology ward in
day 15 for further work up, where coronary angiography was
performed and revealed three vessel diseases. He underwent
coronary artery bypass grafting (CABG) on day 16 and finally
was discharged after 27 days with recommendation to related
cardiologic follow up in outpatient clinic.
3. Discussion:
Potential relationship between opioids and coronary artery
diseases has been widely studies in humans and animals (4-
6). Opioid induced manifestation on coronary artery dis-
ease (CAD) is controversial and ranges from protective ef-
fects to triggering role in patients with coronary artery dis-
ease (1). It was reported that opium consumption may be
positively correlated with the risk of CAD in diabetic opium
addict subjects undergoing coronary angiography. This ef-
fect was dose dependent (7). Abrupt discontinuation of opi-
oids or consumption of opioid antagonists in addict subjects
lead to opioid withdrawal syndrome. This syndrome is con-
sidered to be a true physical stress and presented with agi-
tation, severe muscular pain, vomiting, diaphoresis, rhinor-
rhea and mydriasis. A transient increase in catecholamines
may also cause tachypnea, tachycardia and hypertension,
which has been described as an overshoot phenomenon (8,
9). Altered mental status might also occur. Naltrexone, µ-
and K-receptor antagonist, with a half-life of 10 hours could
induce withdrawal symptoms if administered in opioid de-
pendent cases. Clinical manifestations of withdrawal syn-
drome usually appear within five minutes after consump-
tion of Naltrexone. (10). Catecholamine release could lead
to myocardial stunning and impaired perfusion of coronary
flow reserve (11). Reduced subendocardial perfusion, pul-
monary edema and cardiac arrhythmias are being reported
to be related to catecholamine release in opioid withdrawal
(12, 13). Increased noradrenergic and dopaminergic activity
and consequent effects on heart following opium antagonist
agents administration to morphine-dependent subjects has
also been described in previous animal researches (14-16).
Potential mechanisms could be as follows: decrease in coro-
nary flow reserve; microvascular dysfunction; direct effects of
catecholamines on cardiac myocytes through calcium over-
load mediated by cyclic AMP; oxygen-derived free radicals;
contraction band necrosis which is an interstitial mononu-
clear inflammatory response; thrombosis formation in con-
text of atherosclerotic vessels; increased blood pressure and
ventricular contractility (17-19). This case report describes a
methadone addict individual with underlying ischemic heart
disease who experienced MI following naltrexone consump-
tion. MI occurred in early phase of withdrawal syndrome.
Naltrexone induced physical and emotional stress in a pa-
tient on MMT may cause acute coronary syndrome in a pa-
tient with underlying ischemic heart disease. Naltrexone
should never be prescribed to an opioid addict; If happens,
severe withdrawal syndrome will occur (8, 9). Opioid ad-
dict cases on MMT and their family should be educated for
this serious complication. It is recommended that naltrexone
should be used 10 to 14 days after the last dose of methadone
or at least 7 to 10 days after opium discontinuation (20-22).
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